Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07218341 | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 4 | 150 | Eli Lilly and CompanyINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | recruiting | Phase 1 | 460 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 22, 2026 | clinicaltrials |
| NCT01829958 |
| Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy |
| active not recruiting |
| N/A |
| 201 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Sep 21, 2026 |
| clinicaltrials |
| NCT05296070 | Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma | recruiting | Phase 2 | 50 | University of MiamiOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06029309 | Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma(ZANU-TAFA) | recruiting | Phase 1 / Phase 2 | 27 | Alvaro Alencar, MDOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06549595 | A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients | recruiting | Phase 3 | 1,018 | AstraZenecaINDUSTRY | 24 | Sep 21, 2026 | clinicaltrials |
| NCT04231877 | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | active not recruiting | Phase 1 | 56 | University of WashingtonOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04594798 | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | active not recruiting | Phase 2 | 39 | University of RochesterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05025800 | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05627245 | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | active not recruiting | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07422610 | Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment | recruiting | Phase 1 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 18, 2026 | clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT07221500 | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) | recruiting | Phase 2 | 100 | Nurix Therapeutics, Inc.INDUSTRY | 5 | Sep 17, 2026 | clinicaltrials |
| NCT07341191 | Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy | recruiting | Phase 2 | 40 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 17, 2026 | clinicaltrials |
| NCT02446236 | Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 1 | 27 | Hackensack Meridian HealthOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02629809 | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04002947 | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05757219 | Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy | recruiting | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07343934 | huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma | recruiting | Phase 1 | 6 | University of PennsylvaniaOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04094311 | Study of Out of Specification for Tisagenlecleucel | recruiting | Phase 3 | 200 | Novartis PharmaceuticalsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT06647732 | Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | active not recruiting | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02180724 | An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 107 | Acerta Pharma BVINDUSTRY | 7 | Sep 14, 2026 | clinicaltrials |
| NCT03267433 | Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission | active not recruiting | Phase 3 | 689 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04115631 | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | active not recruiting | Phase 2 | 360 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04246086 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma | active not recruiting | Phase 1 / Phase 2 | 237 | Hoffmann-La RocheINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT07168486 | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | enrolling by invitation | Phase 1 | 15 | University of Maryland, BaltimoreOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07731789 | Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma | not yet recruiting | Phase 2 | 30 | University of WashingtonOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07739459 | Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)(ZEN-CLL) | not yet recruiting | Phase 2 | 95 | The Lymphoma Academic Research OrganisationOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07817641 | Proton Therapy for Mediastinal Lymphoma (PROMLY)(PROMLY) | recruiting | N/A | 139 | Rigshospitalet, DenmarkOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818499 | A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 204 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome | not yet recruiting | Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01318317 | Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 8 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01849263 | Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma | active not recruiting | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 3 | Sep 11, 2026 | clinicaltrials |
| NCT04665765 | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 41 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05934084 | Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors | recruiting | N/A | 552 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06091254 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma(OLYMPIA-1) | recruiting | Phase 3 | 822 | Regeneron PharmaceuticalsINDUSTRY | 19 | Sep 11, 2026 | clinicaltrials |
| NCT06291220 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(453 Ph1 CLL) | active not recruiting | Phase 1 | 4 | AbbVieINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT06492837 | Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients(FIL_MOZART) | active not recruiting | Phase 2 | 56 | Fondazione Italiana Linfomi - ETSOTHER | 2 | Sep 11, 2026 | clinicaltrials |
| NCT06526793 | Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL(SOUNDTRACK-B) | recruiting | Phase 2 | 270 | AstraZenecaINDUSTRY | 16 | Sep 11, 2026 | clinicaltrials |
| NCT06830031 | Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma(C402) | recruiting | Phase 1 | 18 | Shanghai Exuma Biotechnology Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07061951 | Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04169737 | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | recruiting | Phase 2 | 168 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04759586 | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | active not recruiting | Phase 3 | 244 | National Cancer Institute (NCI)NIH | 4 | Sep 10, 2026 | clinicaltrials |
| NCT05272384 | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07570017 | A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 42 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07799220 | A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814001 | Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy(BiFAST) | not yet recruiting | Phase 2 | 55 | The Lymphoma Academic Research OrganisationOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03625037 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma(EPCORE™ NHL-1) | active not recruiting | Phase 1 / Phase 2 | 666 | GenmabINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 22, 2026source: clinicaltrials